Asset Management One Co. Ltd. Has $11.86 Million Stock Holdings in Insulet Corporation $PODD

Asset Management One Co. Ltd. raised its position in Insulet Corporation (NASDAQ:PODD) by 29.0% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 38,401 shares of the medical instruments supplier’s stock after acquiring an additional 8,622 shares during the period. Asset Management One Co. Ltd. owned about 0.05% of Insulet worth $11,858,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in PODD. True Wealth Design LLC lifted its position in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares in the last quarter. Kozak & Associates Inc. acquired a new stake in Insulet in the 2nd quarter valued at $32,000. Golden State Wealth Management LLC lifted its position in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH bought a new stake in Insulet during the 2nd quarter worth about $35,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Insulet during the 2nd quarter worth about $51,000.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Cowen reaffirmed a “buy” rating on shares of Insulet in a research report on Thursday, December 4th. Canaccord Genuity Group raised their price target on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Leerink Partners upped their price objective on Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Stifel Nicolaus began coverage on Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price objective for the company. Finally, UBS Group restated a “buy” rating on shares of Insulet in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $381.75.

Insulet Price Performance

NASDAQ:PODD opened at $294.35 on Wednesday. The company has a market cap of $20.71 billion, a P/E ratio of 85.32, a P/E/G ratio of 1.58 and a beta of 1.40. The firm’s fifty day moving average price is $308.15 and its two-hundred day moving average price is $312.15. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter last year, the company posted $1.08 EPS. Insulet’s quarterly revenue was up 29.9% compared to the same quarter last year. Equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.